jeudi 27 septembre 2018

Onco Actu du 27 septembre 2018

2.5 Etiologie - Gènes

Cancer-related gene associations often reclassified, study says [UPI]

2.7 Etiologie - Obésité

Breaking the link between obesity, gastrointestinal cancers [UNC]

Separating fact from hype in the study of cancer and obesity [The Guardian]

3.4.1 Chimioprévention - aspirine

Aspirin could play key role in treating some cancers [UPI]

3.9 Prévention - Contraceptifs

Contraceptive pill reduces risk of ovarian cancer, study finds [The Guardian]

4.12 Biopsies liquides

Urine liquid biopsies could help monitor bladder cancer treatment [Cancer Research UK]

4.2 Dép., diag. & prono. - Génome

Oregon weighs plan to deny Medicaid payment for NGS as panel declares “no evidence of clinical utility” [The Cancer Letter]

Experts call for genetic testing to personalise treatment for all children assessed for new cancer treatments [Institute of Cancer Research]

5. Traitements

Fecal microbiota transplantation helps restore beneficial bacteria in cancer patients [NIH]

5.12.7 Immunothérapies - vaccins

Stimulating the Immune System Shrinks Some Slow-Growing Lymphomas [NCI]

5.13 WCLC

Study Analyzes Use of Thoracic Radiotherapy for Limited-Stage SCLC [IASLC]

“Patients First”Plenary/ IASLC World Conference on Lung Cancer [IASLC]

5.13.1 WCLC - Immunothérapies

AstraZeneca sharpens Imfinzi's lung cancer edge with big survival win [FiercePharma]

5.13.2 WCLC - Thérapies ciblées

Takeda's Alunbrig trounces Pfizer drug in bid for earlier ALK lung cancer use [FiercePharma]

5.13.3 WCLC - Dépistage

NELSON screening study gives boost to CT screening in Europe [British Thoracic Oncology Group]

Screening scans 'could cut lung cancer deaths’ [Cancer Research UK]

5.2.1 Pharma - Partenariats

U.S.-Cuban biotech venture created to bring new cancer therapies to USA [Reuters]

6.10 Politiques

Brexit is already damaging European science [Nature]

6.9 Controverses

Statement from Cochrane’s Governing Board – 26th September 2018 [Cochrane]